Eliaz Therapeutics

Executive Summary

Eliaz Therapeutics is a San Diego-based MedTech company developing the XGal-3® apheresis device, an FDA Breakthrough-Designated therapy targeting Galectin-3, a key driver of sepsis and chronic inflammatory diseases. Founded in 2020, the company aims to shift treatment from symptom management to source control by selectively removing Galectin-3 from the bloodstream. The device is designed for use in intensive care and chronic disease settings, addressing large unmet needs in life-threatening inflammatory conditions where no targeted therapies exist. With its breakthrough designation, Eliaz has expedited regulatory pathways and is positioned to disrupt the sepsis treatment market, projected to exceed $10 billion by 2030. The company is advancing toward clinical validation, with a focus on demonstrating safety and efficacy in sepsis patients. If successful, the XGal-3 device could become a standard adjunct therapy in ICUs, reducing mortality and progression to multiple organ failure. Beyond sepsis, Eliaz explores applications in fibrosis and autoimmune diseases, expanding its addressable market. While still in early clinical stages, the convergence of breakthrough regulatory status, experienced management, and a novel mechanism of action supports a promising outlook. Key risks include clinical trial enrollment challenges and manufacturing scalability, but near-term catalysts could provide significant value inflection.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Pivotal Sepsis Trial60% success
• Q3 2026FDA Feedback on Breakthrough Device Pathway80% success
• H2 2026Research Collaboration or Grant Announcement70% success